Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s Disease Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s ...
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease - Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn’s A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Activ ...
Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Moderately to Severely Active Crohn’s Disease MedDRA version: 20.0;Level: PT;Classification code 100 ...
Product Name: ozanimod Product Code: [RPC1063] INN or Proposed INN: Ozanimod Product Name: ozanimod Product Code: [RPC1063 equiv to ozanimod HCI] INN or Proposed INN: Ozanimod Product Name: ozanimod Product Code: [RPC1063] INN or Proposed INN: Ozanimod Product Name: ozanimod Prod ...